Chimeric Antigen Receptors (CARs) are engineered proteins that allow T-cells, a type of immune cell, to better recognize and attack cancer cells. By combining antigen-binding domains with T-cell activation domains, CARs enable immune cells to target specific proteins on the surface of cancer cells, offering a promising approach to cancer immunotherapy.